Portfolio company Regenosine receives a $1.67M NIH NIAMS Phase II SBIR grant

Congratulations to portfolio company Regenosine on receiving a $1.67M NIH NIAMS Phase II SBIR grant to commercially develop their disease modifying osteoarthritis drug.

Featured Post

BioNJ Announces Strategic Collaboration with Tech Council Ventures to Boost Life Sciences Innovation

July 9, 2024

BioNJ Announces Strategic Collaboration with Tech Council Ventures to Boost Life Sciences Innovation Trenton, NJ – July 9, 2024– BioNJ,...

TCV Highlights

Play Video

Recent Fund Successes

Play Video

Share This Content

Contact

PO Box 307
Summit, NJ 07902
+1-856-273-6800

About Us

We invest in the most promising early-stage, rapid-growth technology companies in the Mid-Atlantic region.

Spotlight

For Investors

Policies

Featured

BioNJ Announces Strategic Collaboration with Tech Council Ventures to Boost Life Sciences Innovation

July 9, 2024

Website designed by Lookit® Design ,
powered by Lookit® QuikSite.